The gut microbiome in drug-resistant epilepsy

Area of Science:

• Neurology
• Microbiology
• Gastroenterology

Background:

• Approximately one-third of epilepsy patients have drug-resistant epilepsy.
• Intestinal dysbiosis is a potential factor in the pathophysiology of drug resistance.
• The ketogenic diet is a recognized treatment for medically refractory seizures, potentially acting via gut microbiota modulation.

Purpose of the Study:

• To review clinical data on gut microbiome alterations in drug-resistant epilepsy.
• To explore mechanisms by which gut microbiome modifications improve drug-resistant epilepsy.
• To summarize findings from preclinical and clinical studies on gut microbiome interventions.

Main Methods:

• Comprehensive literature search of PubMed, Embase, and Web of Science databases.
• Analysis of clinical studies on gut microbiome profiles in drug-resistant epilepsy patients.
• Review of preclinical and clinical findings on gut microbiome modification methods.

Main Results:

• Evidence suggests alterations in gut microbiome profiles in drug-resistant epilepsy.
• Ketogenic diet, prebiotics, and probiotics are being investigated as therapeutic strategies.
• These interventions may improve drug-resistant epilepsy through mechanisms involving gut microbiota.

Conclusions:

• The gut microbiome represents a promising area for targeted therapeutic interventions in drug-resistant epilepsy.
• Further research is needed to confirm preliminary findings and assess the safety and effectiveness of altering gut bacterial composition.